Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Explore Neural Mechanism of Obsessive-Compulsive Disorder (OCD) by Intervention of Repetitive Transcranial Magnetic Stimulation With Symptom Provocation

2 de julio de 2026 actualizado por: Taipei Veterans General Hospital, Taiwan

The purpose of this study is to investigate the differences in therapeutic efficacy of different deep Transcranial Magnetic Stimulation (deep TMS) treatment coils and different brain stimulation targets on obsessive-compulsive symptoms, and to explore the neural mechanisms of obsessive-compulsive disorder using functional neuroimaging analysis.

  1. Inclusion Criteria:

    Adults aged 18-65 years. Patients diagnosed with obsessive-compulsive disorder according to DSM-5 criteria.

  2. Study Design: Double-blind, randomized assignment.
  3. Number of Participants:

    Sham group: 32 participants Active H7 group: 32 participants Active H1 group: 32 participants Total: 96 participants

  4. Study Procedures:

    - Participant Screening and Baseline Assessment (Week 0) Determine eligibility for enrollment, including diagnostic confirmation, symptom assessment, screening for contraindications, and whether the participant has previously experienced adverse effects following TMS treatment. Participants with high suicide risk within the past year will be excluded.

    Develop a personalized symptom provocation procedure for obsessive-compulsive symptoms.

    Complete baseline symptom severity assessments and brain positron emission tomography/magnetic resonance imaging (PET/MRI). Participants with structural brain abnormalities will be excluded.

    Participants will be randomly assigned (1:1:1) into three groups, with a planned total enrollment of 96 participants.

    Participants currently taking medication may continue their existing regimen, but no medication changes will be allowed during the study period.

    - Treatment Phase (Week 1 to Week 6; duration: 6 weeks) Before each TMS session, participants will remove their shoes and socks, rest both hands flat on their thighs, keep their eyes looking straight ahead, and undergo measurement of resting motor threshold (RMT).

    Approximately 3-5 minutes before each TMS session, trained personnel with Exposure and Response Prevention (ERP) experience will assist participants in symptom provocation and record the participant's subjective level of distress.

    The deep TMS treatment schedule consists of five sessions per week, one session per day, for six consecutive weeks. Adverse effects will be assessed and monitored at each session.

    After completing the first treatment session, participants will be asked to guess which group they were assigned to, in order to evaluate the effect of treatment expectations on outcomes.

    Symptom severity interviews will be conducted every two weeks.

    - Post-treatment Assessment and Follow-up (Week 7 and after; duration: 2 weeks, then 6 months later) Within one week after completion of the deep TMS treatment course (within Week 7), participants will undergo follow-up brain PET/MRI.

    At the end of Week 8 (two weeks after treatment completion), symptom severity will be reassessed. Subsequent treatment plans will be discussed with participants, and outpatient follow-up will be arranged within six months.

    Subsequent treatment options may include cognitive behavioral therapy, pharmacotherapy, and figure-8 rTMS.

  5. Statistical Analysis

    • Expected Outcomes:

The H7 coil may improve obsessive-compulsive symptoms. Both the H7 and H1 coils may improve mood symptoms.

- Descriptive and Inferential Statistics: Analysis of covariance (ANCOVA) will be used to compare differences among the three groups in Montgomery-Asberg Depression Rating Scale (MADRS), Yale-Brown obsessive compulsive scale (Y-BOCS), Hamilton Anxiety Scale (HAM-A), Hamilton Depression Scale (HDRS), and Clinical Global Impression (CGI-S) scores.

The percentage of responders (% responders) will be calculated and compared among groups.

Repeated-measures ANOVA will be used to examine within-group and between-group differences in symptom improvement before and after deep TMS treatment.

Pearson correlation analysis will be used to assess the association between symptom improvement and changes observed in PET/MRI neuroimaging measures.

- PET/MRI Neuroimaging Analysis: Functional MRI analyses will include ROI-to-ROI functional connectivity and seed-based functional connectivity analyses.

Changes in PET glucose uptake within specific regions of interest (ROIs) will also be examined to evaluate alterations in neural networks and brain function before and after deep TMS treatment.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

96

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Cheng-Ta Li
  • Número de teléfono: 886-2-55704055
  • Correo electrónico: ctli0420@gmail.com

Copia de seguridad de contactos de estudio

Ubicaciones de estudio

      • Taipei, Taiwán
        • Reclutamiento
        • Taipei Veterans General Hospital
        • Contacto:
          • Cheng-Ta Li
          • Número de teléfono: 886-2-55704055
          • Correo electrónico: ctli0420@gmail.com
        • Contacto:

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

No

Descripción

Inclusion Criteria:

  • Adults aged 18-65 years.
  • Diagnosis of obsessive-compulsive disorder according to DSM-5 criteria. Treatment resistance (i.e., inadequate response to pharmacological or non-pharmacological treatments) is not required.
  • Yale-Brown Obsessive Compulsive Scale (Y-BOCS) score ≥ 14, indicating at least mild to moderate symptom severity.

Exclusion Criteria:

  • Diagnosis of schizophrenia, organic psychotic disorder, bipolar disorder, alcohol use disorder, or substance use disorder.
  • High suicide risk within the past year.
  • Presence of significant medical or surgical conditions in an active phase.
  • History of, or planned, neurosurgical procedures, or presence of metallic implants in the brain or body (e.g., neurostimulators or cardiac pacemakers).
  • Structural brain abnormalities (e.g., brain tumor or arteriovenous malformation) or neurological disorders (e.g., meningitis, encephalitis, stroke, or epilepsy).
  • Pregnant women.
  • Inability to tolerate PET/MRI examination due to claustrophobia or severe anxiety in confined spaces.
  • Any other conditions that may impair study compliance, including inability to cooperate, failure to provide informed consent, or other investigator-determined ineligibility after screening.
  • Use of medications that may increase seizure risk or suicide risk (e.g., certain antidepressants or antipsychotics).
  • Known allergy to 18F-FDG (18F-2-Fluoro-2-DeoxyGlucose).
  • History of adverse reaction to TMS or allergy to the positioning cap.
  • Presence of metallic objects within approximately 30 cm of the cranial region (within the stimulation coil area).
  • Prior or current treatment with electroconvulsive therapy (ECT) or vagus nerve stimulation (VNS).

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Cuadruplicar

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Active H7 coil stimulation

Sham dTMS Participants will receive sham deep TMS using a sham coil.

H7 dTMS Participants will receive active deep TMS using the H7 coil.

H1 dTMS Participants will receive active deep TMS using the H1 coil.

Comparador falso: Sham stimulation group

Sham dTMS Participants will receive sham deep TMS using a sham coil.

H7 dTMS Participants will receive active deep TMS using the H7 coil.

H1 dTMS Participants will receive active deep TMS using the H1 coil.

Experimental: Active H1 coil group

Sham dTMS Participants will receive sham deep TMS using a sham coil.

H7 dTMS Participants will receive active deep TMS using the H7 coil.

H1 dTMS Participants will receive active deep TMS using the H1 coil.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
the percentage changes in Y-BOCS scores after treatments
Periodo de tiempo: the 6-week and 8-week

Two time-spans are assessed: (a) from baseline (Week 0, W0) to posttreatment (Week 6, W6), and (b) from baseline (W0) to the 2-week follow-up (Week 8, W8). The percentage changes in Y-BOCS scores will be calculated as follows:

  1. percent of YBOCS6-0 = (W6 - W0) / W0
  2. percent of YBOCS8-0 = (W8 - W0) / W0 A full treatment response, defined as a ≥30 percent reduction in Y-BOCS score from baseline, will be evaluated at both the 6-week and 8-week time points.
the 6-week and 8-week

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

22 de septiembre de 2025

Finalización primaria (Estimado)

31 de diciembre de 2027

Finalización del estudio (Estimado)

31 de diciembre de 2027

Fechas de registro del estudio

Enviado por primera vez

8 de mayo de 2026

Primero enviado que cumplió con los criterios de control de calidad

8 de mayo de 2026

Publicado por primera vez (Actual)

14 de mayo de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

6 de julio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

2 de julio de 2026

Última verificación

1 de julio de 2026

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • 2024-06-004C

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Patient privacy

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir